Prescribing Alprazolam (Xanax)

Why Alprazolam Deserves a Careful Hand

Alprazolam is the most prescribed, and most argued-about, benzodiazepine in America. It is a fast-acting, potent triazolobenzodiazepine that can abort a panic attack in twenty minutes, and it is also the benzodiazepine with the highest toxicity index, the greatest abuse liability, and the nastiest withdrawal syndrome in its class. Both of those statements are true at once, and prescribing it well means holding them together.

The drug arrived in 1981, timed almost perfectly to the DSM-III's newly minted "panic disorder" diagnosis, and Upjohn marketed it hard into that space. It worked. Alprazolam remains FDA-approved for panic disorder and generalized anxiety disorder, and for the right patient (infrequent panic, situational phobia, acute anxiety that needs relief now rather than in four weeks) nothing in the pharmacopeia is faster or more reliable.

The problem is that alprazolam's very virtues are its liabilities. Its rapid onset and short clinical duration make it feel wonderful and wear off quickly, which is exactly the pharmacology that drives clock-watching, inter-dose rebound, dose creep, and a taper that can take months. Its potency means small milligram errors matter. And its combination with opioids or alcohol can kill.

So the thesis of this guide is not "avoid alprazolam": the reflexive benzophobia of the last decade has left plenty of panic-disorder patients undertreated. The thesis is that alprazolam is a legitimate, effective, often underappreciated tool when you match it to the right indication, respect its short half-life and abuse profile, screen hard for opioids and active substance use, and never start it without a plan for how it ends. Prescribe it that way and you have one of the most effective acute anxiolytics ever made. Prescribe it carelessly and you have manufactured a dependence problem that will outlast the anxiety you were treating.

Part 1: Indications: Who Is Alprazolam For?

FDA-Approved Uses

• Panic disorder (with or without agoraphobia): the flagship indication, best evidence
• Generalized anxiety disorder (GAD) and anxiety disorders generally

The Evidence-Based Clinical Uses

Panic disorder, the home turf. This is where alprazolam earns its keep. It has the most empiric support of any anxiety indication, it is FDA-approved, and it works within minutes to hours rather than the two to four weeks an SSRI demands. A meta-analysis (Chawla et al., BMJ 2022) found benzodiazepines somewhat more likely to produce remission in panic than SSRIs, at the cost of more adverse effects. For a patient in the throes of frequent, disabling panic who cannot wait a month for an antidepressant to work, alprazolam delivers.

Infrequent panic attacks (as-needed). For a patient who panics once or twice a month, a PRN 0.5 mg tablet in the pocket is often better medicine than a daily SSRI, both for efficacy and for the confidence that simply carrying it provides.

Situational and specific phobias, especially flying. Flying phobia is arguably alprazolam's single cleanest use case: an infrequent, predictable, time-limited trigger where as-needed dosing gives consistent relief and where daily-medication downsides never accrue. Driving phobia is a more cautious application (impairment matters when the patient then drives), and other circumscribed social/performance situations can qualify.

Acute anxiety requiring rapid relief. A panic attack in your office; an acute, self-limited stressor (a death, a move, a deadline) producing crisis-level anxiety or insomnia; bridging a patient through the two-to-four-week lag while an SSRI takes hold. Alprazolam's speed is the entire point in these settings.

GAD, a real but last-resort indication. Alprazolam is FDA-approved for GAD, but for chronic anxiety it belongs after SSRIs, SNRIs, buspirone, and CBT have been tried, because chronic anxiety implies chronic dosing, and chronic dosing is where the dependence, tolerance, and cognitive problems live. When used, alprazolam XR at 0.5 to 2 mg once or twice daily is the more defensible formulation.

Worst Uses: Where Alprazolam Does Not Belong

• OCD: no benefit for core symptoms.
• PTSD: scant evidence; may interfere with exposure-based recovery and worsen long-term outcomes.
• Chronic insomnia: tolerance to the hypnotic effect develops fast, and short-acting IR produces middle-of-the-night rebound awakenings.
• Active substance use disorder: high abuse potential in this specific population (see Part 8).
• Concurrent opioid use: this is a contraindication, not merely a caution (see Parts 6 and 7).
• Borderline or antisocial personality disorder: risk of disinhibition and behavioral dyscontrol. In a placebo-controlled BPD trial, alprazolam (mean about 4.7 mg/day) actually worsened behavioral dyscontrol.

The CBT Paradox: an indication-shaping caveat

Cognitive behavioral therapy for anxiety works by exposure and habituation: the patient must experience anxiety, sit with it, and relearn that it is survivable. Alprazolam, by pharmacologically erasing the anxiety, can rob a patient of the very experience CBT depends on, especially with PRN dosing, where the patient reaches for a pill the moment discomfort rises and never habituates.

Part 2: Before You Start: Candidacy and Workup

Alprazolam requires no baseline labs or serum monitoring. The workup is entirely clinical, and it is mostly a screen for the things that turn a useful drug into a dangerous one.

Screen every candidate for

Set expectations and document before the first prescription

• Explain that physiologic dependence is expected with regular use for several weeks, and that this is not the same as addiction.
• Explain that you will not stop it abruptly, and that any discontinuation will be a slow, planned, joint taper.
• Warn explicitly about driving at peak levels (30 to 60 minutes post-dose, when reaction time is most impaired), and about alcohol and opioids.
• For any long-term or off-label use, document the risk-benefit discussion. A defensible note reads roughly: "Patient has severe, treatment-resistant symptoms; given failure of first-line options, the risk of the benzodiazepine appears justified. Risks including driving impairment, falls, dependence, and interaction with alcohol/opioids were discussed."

Part 3: How to Start and Dose

Formulations

• Immediate-release (IR) tablets: the standard. Fast onset (GI absorption in about 20 to 30 minutes; peak plasma 1.5 to 2 hours), short clinical duration (about 3 to 4 hours despite a 10 to 15 hour half-life). Available in 0.25, 0.5, 1, and 2 mg. The 2 mg "bar" is scored into quarters.
• Extended-release (Xanax XR): approved 2003 for panic disorder; a hydroxypropyl-methylcellulose matrix releasing over more than 10 hours, peaking around 9 hours. Dosed once (or twice) daily. Produces smoother levels, less inter-dose rebound, and, importantly, lower abuse liability (in abuse-history volunteers, XR did not differ from placebo on abuse measures while IR did). A high-fat meal speeds XR release, risking an early peak and later inter-dose withdrawal.
• Orally disintegrating tablets and liquid concentrate exist; the liquid is invaluable for fine taper titration.
• Sublingual use: not an official formulation, but crushing/dissolving an IR tablet under the tongue speeds onset by partially bypassing first-pass metabolism. Useful when very rapid relief is the goal.

Dosing by indication

Acute panic attack (as-needed)

• 0.5 mg is the standard single dose; up to 1.0 mg for larger patients or severe attacks.
• May redose every 20 to 30 minutes if the attack continues.

Panic disorder (daily maintenance)

• Typical therapeutic range 2 to 5 mg/day, usually divided.
• Trials establish safety up to 6 to 10 mg/day, with 10 mg/day the practical maximum, but doses in that range should prompt a hard look at whether the diagnosis and plan are right.
• Because IR lasts only about 3 to 4 clinical hours, daily dosing often requires TID to QID to avoid inter-dose rebound. This dosing-frequency burden is a major argument for XR or for a longer-acting agent.

GAD (when used)

• Alprazolam XR 0.5 to 2 mg once or twice daily.

Situational/phobia (as-needed, e.g., flying)

• Take a dose ahead of the trigger to "get ahead of the anxiety," the night before or en route, analogous to staying ahead of pain. Redose every 20 to 30 minutes if anxiety persists. The worst realistic outcome is that the patient sleeps.

Standing vs. PRN: a decision that shapes everything

Rule of thumb: if a "PRN" patient is using it more than about 50% of days, that is a signal to either convert to a scheduled dose or reassess the whole plan, since it usually means the underlying disorder needs better baseline treatment, not more benzodiazepine.

Dose equivalencies (for switching)

These are approximations and vary substantially patient to patient; when switching, cross-taper rather than swap one-for-one.

Part 4: Mechanism and Pharmacokinetics: Why It Behaves This Way

Alprazolam is a positive allosteric modulator at the GABA-A receptor. It binds the benzodiazepine site adjacent to the receptor and enhances the ability of native GABA to open the chloride channel, "turbocharging" endogenous inhibition and dampening neuronal firing across the brain. It acts at both the alpha-1 subunit (which mediates sedation) and the alpha-2 subunit (which mediates anxiolysis), unlike the z-drugs, which are largely alpha-1-selective. It does not create inhibition where GABA is absent; it amplifies what is already there, which is why benzodiazepines are relatively safe alone.

The clinically decisive fact about alprazolam is the disconnect between its half-life and its duration of action. Its elimination half-life is 10 to 15 hours, yet its clinical effect lasts only about 3 to 4 hours. Duration of action is governed by lipophilicity and redistribution, not half-life, so a drug can leave the brain (ending the clinical effect) long before it leaves the body (ending the elimination). This is why alprazolam feels short-acting and requires frequent dosing despite a half-life that, on paper, looks intermediate.

Metabolism: hepatic, via CYP3A4 (with a CYP2C-family contribution). Unlike the "LOT" benzodiazepines (lorazepam, oxazepam, temazepam), which are cleared by phase-II glucuronidation and dodge most drug interactions, alprazolam runs through the CYP system, so it is vulnerable to CYP3A4 inhibitors and accumulates in liver disease.

Part 5: Side Effects and How to Manage Them

The governing principle: most alprazolam side effects are mild, transient, and dose-related, but the ones that matter (cognitive impairment, falls, and inter-dose rebound) are insidious and easy to miss.

Sedation

Common early, usually mild, and typically resolves within days as tolerance to the sedative effect develops. (Reassuringly, tolerance develops to sedation but usually not to the anxiolytic effect.)

Management: reassure that it is temporary; if persistent, shift dosing earlier in the evening, lower the dose, or switch formulation.

Cognitive impairment: the quiet, underrecognized one

This is the side effect prescribers most often miss. Chronic benzodiazepine use dulls memory, processing speed, and attention across multiple domains, with moderate-to-large effect sizes in meta-analyses. It accumulates slowly, the patient normalizes it, and neither party attributes it to the drug. Some impairment is detectable up to a year after stopping.

Management:

• Screen actively in chronic users, asking about mental sharpness, not just anxiety.
• Consider a periodic supervised tapering trial specifically to unmask occult cognitive effects. Many long-term users report an "awakening" of clear-mindedness after coming off.
• XR is associated with less cognitive/motor impairment than IR in trials, a point in its favor for patients who need daily coverage.

Motor impairment and falls

Impaired coordination and reaction time; reaction time is most impaired 30 to 60 minutes after the dose peak, even in patients on stable chronic doses. In older adults the fall risk is roughly 1.5-fold, highest in the first two weeks, and motor-vehicle-accident risk is meaningfully elevated.

Management:

• Counsel against driving at peak levels, for every patient, not just new starts.
• In anyone with fall risk, question whether alprazolam is the right drug at all.
• IR causes measurable motor impairment in abuse-liability trials; XR does not, another reason to prefer XR when daily dosing is unavoidable.

Inter-dose rebound and morning symptoms

Because IR is short-acting, it can wear off between doses (rebound anxiety) or mid-sleep (middle-of-the-night awakening when misused for insomnia). Morning grogginess is uncommon but possible.

Management: switch to a longer-acting agent or to XR; for rebound anxiety, resist the urge to simply add more frequent IR dosing, which deepens the dependence loop.

Paradoxical disinhibition

Uncommon but real: agitation, impulsivity, aggression, or self-harm, most likely in personality-disordered patients, the developmentally disabled, and the demented/elderly. A large cohort study even associated benzodiazepines with elevated violent-crime risk (likely partly confounded by indication, but the paradoxical-reaction signal is genuine).

Management: avoid alprazolam in BPD/ASPD and in patients with a violence history; if disinhibition emerges, discontinue (via taper).

Respiratory depression

Minimal with alprazolam alone in healthy patients, but a serious concern in COPD/OSA and catastrophic when combined with opioids or alcohol (see Part 6).

Part 6: Overdose, Toxicity, and the Boxed Warning

Alprazolam alone

Like all benzodiazepines, alprazolam is rarely fatal in isolated overdose. It produces deep sedation, ataxia, slurred speech, and confusion, but, because it amplifies GABA rather than directly depressing the brainstem, breathing is usually preserved. That said, alprazolam carries one of the highest toxicity indices of any benzodiazepine (lorazepam and oxazepam among the lowest), meaning that dose-for-dose it is more dangerous in overdose than its peers, and disproportionately implicated in benzodiazepine-related deaths.

The lethal combinations, the boxed warning

Benzodiazepines carry an FDA boxed warning against concurrent opioid use. Both classes suppress respiration through different mechanisms, benzodiazepines via GABA-A, opioids via the medullary respiratory centers, and the effect is additive-to-synergistic and frequently fatal.

• Co-prescription of an opioid raises opioid-related overdose death 2 to 4 fold (large veteran cohorts).
• Risk rises with benzodiazepine dose and does not differ between daily and PRN dosing: an occasional pill is not a safe pill in an opioid user.
• Alprazolam's high toxicity index makes it among the worst benzodiazepines to combine with an opioid.
• Alcohol produces the same additive respiratory-depressant danger.

Flumazenil

The benzodiazepine antagonist reverses effects in a monitored ED/ICU setting but is not safe for routine or home use: in a dependent patient it can precipitate withdrawal seizures, and it can worsen outcomes in mixed benzodiazepine-opioid or tricyclic co-ingestions. For a chronic alprazolam user in overdose, supportive care generally beats flumazenil.

Withdrawal seizures

Distinct from overdose but the other tail-risk: abrupt cessation of high-dose alprazolam carries roughly a 3% seizure rate in high-dose, abruptly-stopped patients. Serious withdrawal (seizures, delirium) is rare at therapeutic doses without concurrent alcohol or illicit-drug use, but it is more likely with alprazolam than most benzodiazepines because of its short half-life and steep offset. If you are worried about a high-dose taper, prescribe an anticonvulsant cover (e.g., carbamazepine or valproate) or manage the taper in a monitored setting.

Part 7: Drug Interactions

The dangerous pharmacodynamic interactions

• Opioids: boxed-warning combination; potentially fatal respiratory depression. Effectively contraindicated (see Part 6).
• Alcohol: additive CNS and respiratory depression; fatal at high levels, accident-provoking at moderate levels. Counsel every patient explicitly.
• Other sedative-hypnotics: z-drugs, other benzodiazepines, sedating antipsychotics, muscle relaxants, gabapentinoids: additive CNS depression. Avoid stacking.

The pharmacokinetic interactions (alprazolam's Achilles' heel)

Because alprazolam is a CYP3A4 substrate, inhibitors raise its levels and can produce excess sedation and impairment:

• CYP3A4 inhibitors (raise alprazolam levels, reduce dose): fluoxetine, fluvoxamine, certain oral contraceptives, and, more potently, from general class pharmacology, azole antifungals (ketoconazole, itraconazole), macrolides (clarithromycin, erythromycin), protease inhibitors, and grapefruit juice (weaker).
• CYP3A4 inducers (lower alprazolam levels, may lose efficacy): carbamazepine and other enzyme inducers.

Part 8: Special Populations

Elderly (>65)

Largely a population to avoid alprazolam in. Older adults face heightened fall risk (with hip fractures that can be fatal), delirium, and insidious cognitive impairment; the Beers Criteria advise against benzodiazepines in this group generally. When a benzodiazepine is genuinely needed, prefer a LOT drug (lorazepam or oxazepam): glucuronidated, no active metabolites, no hepatic interactions, no accumulation. If alprazolam is used, use the lowest possible dose and watch for the tell-tale signs of hidden toxicity: "I wake up exhausted," "it takes me three hours to get dressed," "I go back to bed after breakfast."

Hepatic impairment

Alprazolam is hepatically metabolized and accumulates in cirrhosis/significant liver disease. Prefer the LOT drugs, whose phase-II glucuronidation is relatively preserved in liver disease. If alprazolam must be used, reduce the dose and lengthen the interval.

Renal impairment

Not a major consideration for alprazolam specifically: no routine dose adjustment or serum monitoring is standard, though, as with any CNS depressant, use conservative dosing in advanced renal disease and in the frail.

Pregnancy

Benzodiazepines cross the placenta. Older data raised concern about first-trimester cleft-palate risk; more recent data have weakened, though not entirely erased, that association, and the class is now viewed as less categorically dangerous than it once was. The genuine risks are late-pregnancy fetal exposure with neonatal withdrawal and "floppy baby" sedation after delivery.

A reasonable framework:

• Prefer non-pharmacologic treatment (CBT, psychotherapy) and optimize an antidepressant where anxiety/panic allows.
• If a benzodiazepine is necessary, occasional, intermittent, low doses, especially after the first trimester, do not appear to be clearly harmful, and a shorter-acting agent limits fetal accumulation.
• Weigh the real harm of untreated severe panic/anxiety against fetal risk; do not reflexively stop everything.
• Coordinate with obstetrics; taper toward delivery where feasible to reduce neonatal withdrawal/sedation.

Lactation

Benzodiazepines pass into breast milk in small amounts; risk is mainly with chronic dosing. Lorazepam and oxazepam are the preferred agents if breastfeeding: short half-life, no active metabolites, low milk transfer. Alprazolam is not first choice; if used, favor low, intermittent dosing and watch the infant for sedation, poor feeding, and lethargy.

Children and adolescents

Alprazolam has no established role in pediatric anxiety and is not recommended; first-line care is SSRIs and CBT.

Substance use, where the abuse risk actually concentrates

This is worth stating plainly because the topic is fogged by hysteria:

• In the general therapeutic population, benzodiazepine abuse is rare. APA task-force data put actual abuse at under 1% of patients; clinical trials show little preference for benzodiazepines over placebo; and epidemiologically, most community patients take fewer doses than prescribed and decrease rather than escalate over time. Dose escalation is uncommon in therapeutic users.
• The risk concentrates almost entirely in people with active substance use. In one study of 30 benzodiazepine-dependent patients, 28 were simultaneously abusing other substances. Opioid users specifically abuse benzodiazepines to enhance the opioid "high."
• Alprazolam is the benzodiazepine most sought after for abuse, with high potency, fast onset, IR formulation. XR blunts this (indistinguishable from placebo on abuse measures in abuse-history volunteers).
• Exception worth knowing: patients in stable, remote alcohol recovery can often use benzodiazepines safely; a 12-year naturalistic study found no relapse, tolerance, or new addiction. Active use, however, is a contraindication.

Part 9: Discontinuation: The Hardest Taper in the Class

Stopping alprazolam badly is where most of its damage is done, and its short half-life makes it one of the most unforgiving benzodiazepines to withdraw. Plan the ending at the beginning.

The physiology

Chronic use upregulates the system; abrupt removal leaves neuronal firing unopposed. Alprazolam's short duration means blood levels fall fast between and after doses, so withdrawal comes on quickly and sharply. Expect, and warn about, rebound anxiety, insomnia, tremor, sweating, perceptual changes, and paresthesias. In high-dose abrupt cessation, about 3% seize.

Distinguish the three things you'll see

• Rebound anxiety: a transient overshoot of the original symptom; often the unmasking of the underlying disorder.
• True withdrawal: a distinct syndrome on the timeline above.
• Protracted (post-acute) withdrawal (PAWS): anxiety, cognitive fog, paresthesias, tinnitus, and mood lability persisting beyond the 4 to 6 week acute phase, sometimes for months. Frequently misread as relapse or a new disorder. Prevention (slow taper) beats rescue.

These are often impossible to cleanly separate in real time, which is itself a reason to go slow.

How to taper alprazolam

A published, alprazolam-specific schedule:

• Doses >2 mg/day: reduce by 0.25 mg every 2 days.
• Doses ≤2 mg/day: reduce by 0.125 mg every 2 days.
• This lands roughly at about 5% reduction every 2 days, giving about 5 weeks for a 2 mg/day patient and about 7 weeks for a 4 mg/day patient as a minimum.

The more durable principle: fast at first, slow at the end. The first about 50% of the dose usually comes off more easily; the last about 50%, and especially the final milligrams, must come off very slowly. A hyperbolic taper (roughly 10%/week early, decelerating as the residual dose shrinks) fits the receptor pharmacology better than a linear one. For long-term users, taper over months, sometimes a year or more.

Practical taper technique

• Never dose-skip to taper. With a short-acting drug this produces blood-level swings and withdrawal between doses. Reduce the daily amount consistently instead.
• Use fine-dose tools: alprazolam liquid concentrate and a pipette, or ground-tablet-in-water dilution, or a compounding pharmacy's custom capsules/tapering strips, allow sub-milligram steps.
• Consider switching to a longer-acting agent (clonazepam, or classically diazepam) to smooth the taper, useful for some patients, though current guidance leans toward tapering the drug the patient is already on rather than an automatic switch, and diazepam's accumulation makes it a poor choice in the elderly.
• Write the schedule down. Patients value a concrete, printed taper plan, and it improves adherence.
• Pair with CBT. No medication reliably treats benzodiazepine withdrawal; the evidence-based supports are behavioral (CBT-I for sleep is as effective as a benzodiazepine). Adjuncts like propranolol, pregabalin, gabapentin, or carbamazepine have limited support and are not first-line.
• Make it a joint project. The taper fails when the prescriber wants off and the patient wants on. Offer choices ("Good month? Want to hold here two more weeks?"), and frame each reduction as progress the patient controls.

What success looks like

Roughly 40 to 50% of patients successfully discontinue after a proper taper. Success correlates with lower baseline anxiety, lower daily dose, and shorter duration of use. When a taper genuinely fails after repeated good-faith attempts, maintaining the patient on a reduced dose is a legitimate harm-reduction strategy, far safer than high-dose continuation, and better than a forced withdrawal the patient cannot tolerate. Note, too, that recent data suggest forced benzodiazepine withdrawal can slightly raise mortality even in high-risk groups; deprescribing is usually right, but it is not an emergency to be pursued against the patient's stability.

Part 10: Alprazolam vs. the Alternatives

Alprazolam vs. other benzodiazepines

The honest summary is that alprazolam is rarely the best benzodiazepine for a given job: it is the fastest and most potent, but it pays for that with the shortest clinical duration, the highest abuse liability, the highest toxicity index, and the hardest taper.

• vs. Lorazepam: Lorazepam has a slightly slower onset but similar clinical duration, no active metabolites, and, critically, glucuronidation metabolism that spares it from CYP interactions and hepatic accumulation. Lorazepam is the better default in the elderly, the hepatically impaired, and the polypharmacy patient, and it has a much lower toxicity index.
• vs. Clonazepam: Slower onset but a genuinely longer clinical duration and long half-life, so it can be dosed once or twice daily and produces far less inter-dose rebound. For a patient who needs steady daily panic coverage, clonazepam's smoother pharmacokinetics make it the more sensible standing agent; it is also somewhat less abusable than alprazolam IR. (Its long half-life, however, raises fall risk in the elderly.)
• vs. Diazepam: Diazepam is fast-onset (high lipophilicity) but, like alprazolam, has a short clinical duration despite a very long half-life, and it accumulates badly in chronic use and in the elderly. Its 2 mg tablets and liquid make it a classic taper vehicle.
• vs. Oxazepam: Oxazepam has the slowest onset (least abusable) and the lowest fatality index: the safest benzodiazepine, and the mirror image of alprazolam.
• Speed ranking (onset): Alprazolam IR > lorazepam > clonazepam > alprazolam XR.
• IR vs. XR (within alprazolam): XR delays the peak to about 9 hours, extends duration past 10 hours, reduces inter-dose rebound, causes less cognitive/motor impairment, and is meaningfully less abusable. If a patient needs daily alprazolam, XR is usually the better formulation, with the one caveat that a high-fat meal accelerates its release.

Alprazolam vs. SSRIs/SNRIs for panic and GAD

• Benzodiazepines win on speed (minutes to hours vs. 2 to 4 weeks) and are at least comparable, perhaps modestly superior, on remission in panic.
• SSRIs/SNRIs win on the long game: no tolerance, no dependence, no abuse, and durable benefit. They are first-line for chronic anxiety and panic; alprazolam is best as a bridge, an adjunct for acute distress, or a PRN for the infrequent flare.
• The combination strategy: start the SSRI, use alprazolam for immediate relief during the antidepressant's onset lag, then wean the benzodiazepine, while remembering the CBT caveat.

Alprazolam vs. beta-blockers for performance/social anxiety

For circumscribed performance anxiety, propranolol is often the better tool: non-sedating, cognitively unimpairing, no dependence, and it targets the physical symptoms (tremor, palpitations) directly. Alprazolam reduces anxiety more broadly but sedates and impairs. Reserve alprazolam for performance anxiety that beta-blockade doesn't cover.

So when is alprazolam the right choice?

When you specifically need maximal speed and potency for an infrequent or short-term target (an acute panic attack, a flying phobia, a bridge through an SSRI lag, a crisis-level acute stressor) in a patient with no opioid use, no active substance use, no significant respiratory or hepatic disease, and no advanced age. In that patient, alprazolam is superb. Outside those bounds, a LOT drug, clonazepam, an antidepressant, or a beta-blocker will usually serve the patient better.

The Bedside Cheat Sheet